May 20 (Reuters) - CUREVAC NV 5CV.DE:
Q1 REVENUE EUR 900 THOUSAND
Q1 PRETAX PROFIT EUR -51.7 MILLION
Q1 EBIT EUR -54.7 MILLION
STRONG CASH AND CASH EQUIVALENTS POSITION OF EUR 438.3 MILLION AS OF MARCH 31, 2025
REAFFIRMING EXPECTED CASH RUNWAY INTO 2028
YEAR-ON-YEAR DECREASE IN REVENUES WAS PRIMARILY DRIVEN BY LOWER REVENUES FROM GSK FOLLOWING RESTRUCTURING OF PARTNERSHIP IN JULY 2024 FROM A COLLABORATION INTO A LICENCE AGREEMENT AS WELL AS LOWER SALES TO CRISPR THERAPEUTICS
NET FINANCIAL RESULT FOR Q1 OF 2025 AMOUNTED TO EUR 3.0 MILLION
Source text: ID:nEQ75HTCZa
Further company coverage: 5CV.DE
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.